Science / Biotech / BioTech / Life Science / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / Aetna / Allergan / AnaptysBio / Arcturus Therapeutics / Aslan Pharmaceuticals / Auris Health / BioHaven Pharmaceuticals / BlueBird Bio / cancer / cancer immunotherapy / CAR-T / Celgene / Clinical Trial / CRISPR / dorzagliatin / Edge Therapeutics / emicizumab / EY / FDA / Food and Drug Administration / Gene editing / Gene Therapy / Genentech / GlaxoSmithKline / Hemophilia Federation of America / Homology Medicines / Hua Medicine / institute for clinical and economic review / investing / IPO / John and Laura Arnold Foundation / Joseph Payne / Kymriah / Life Sciences / Multiple Myeloma / Novartis / PAtients For Affordable Drugs / Pfizer / Protagonist Therapeutics / rare disease drugs / rimegepant / RoboticsAI / Roche / Securities and Exchange Commission / Shire / startups / Surface Oncology / surgical robots / Takeda Pharamceutical / Tempest Therapeutics / Type 2 Diabetes / ubrogepant / ulcerative colitis / UnitedHealthcare / Unum Therapeutics / varlitinib / Yescarta

Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

Posted on: Mar 30, 2018   |   Posted by: Biotech Mag

Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

If the recent IPO activity seems to be on overdrive, it's not your imagination. The number of companies filing to go public in the U.S. in the first quarter was up 44 percent...

Continue reading ...



Other Posts from Biotech Mag